Table 6.
Association of CYP2D6 Metabolizer Status (based on genotype and drug inhibitor) with Breast Cancer Risk
| Treatment | Status | Extensive (baseline) |
Intermediate | Poor | Metabolizer status unknown |
|---|---|---|---|---|---|
| Tamoxifen | Controls | 202 | 295 | 93 | 5 |
| Cases | 111 | 156 | 48 | 3 | |
| Odds Ratio | 1 | 0.957 | 0.942 | ||
| 95% CI | (0.697–1.315) | (0.609–1.458) | |||
| p-value | 0.787 | 0.789 | |||
| Raloxifene | Controls | 184 | 250 | 94 | 3 |
| Cases | 83 | 134 | 56 | 0 | |
| Odds Ratio | 1 | 1.196 | 1.306 | ||
| 95% CI | (0.852–1.679) | (0.857–1.992) | |||
| p-value | 0.3 | 0.214 | |||
| Total | Controls | 386 | 545 | 187 | 8 |
| Cases | 194 | 290 | 104 | 3 | |
| Odds Ratio | 1 | 1.064 | 1.112 | ||
| 95% CI | (0.844–1.341) | (0.822–1.505) | |||
| p-value | 0.599 | 0.491 | |||